All In Biotech

NDA 215344 · Azurity

Suflave

Magnesium Sulfate, Polyethylene Glycol 3350, Potassium Chloride, Sodium Chloride, Sodium Sulfate · Oral

Last checked: Nov 19, 2026Latest source record: Jun 15, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Jun 15, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1

0 Phase 3, 1 recruiting

FAERS reports

108

15 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 8, 2026.

SUFLAVE is indicated for the cleansing of the colon as a preparation for colonoscopy in adults. SUFLAVE is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SUFLAVE · MAGNESIUM SULFATE 0.9GM/BOT; POLYETHYLENE GLYCOL 3350 178.7GM/BOT; POTASSIUM CHLORIDE 1.12GM/BOT; SODIUM CHLORIDE 0.5GM/BOT; SODIUM SULFATE 7.3GM/BOT · FOR SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Suflave" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea29
  • vomiting23
  • abdominal distension12
  • headache10
  • dehydration8
  • drug ineffective8
  • pruritus8
  • abdominal pain7
  • dizziness7
  • urticaria7
  • abdominal pain upper5
  • asthenia5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20221
202439
202547
202621

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Suflave (PEG 3350/Sod Sulf,Chlr/Pot/Mag)

2024 spending

$3.7M

Beneficiaries

29,704

30,370 claims

Per beneficiary

$125

$61.40 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$461,517
2024$3,717,028

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.